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Abstract
Adipose-derived stromal cells (ASCs) are pluripotent cells that have the capacity to differentiate into tendon
fibroblasts (TFs). They are abundant in adults, easy to access, and are therefore an ideal cell source for tendon
tissue engineering. Despite this potential, the molecular cues necessary for tenogenic differentiation of ASCs are
unknown. Unlike other bone morphogenetic proteins (BMPs), BMP12, BMP13, and BMP14 have been reported to be
less osteo-chondrogenic and to induce tendon rather than bone formation in vivo. This study investigated the effects
of BMP12 and BMP14 on ASC differentiation in vitro. In canine ASCs, BMP12 effectively increased the expression of
the tendon markers scleraxis and tenomodulin at both mRNA and protein levels. Consistent with these results,
BMP12 induced scleraxis promoter driven-GFP and tenomodulin protein expression in mouse ASCs. Although
BMP12 also enhanced the expression of the cartilage matrix gene aggrecan in ASCs, the resulting levels remained
considerably lower than those detected in tendon fibroblasts. In addition, BMP12 reduced expression of the bone
marker osteocalcin, but not the osteogenic transcription factor runx-2. BMP14 exhibited similar, but marginally less
potent and selective effects, compared to BMP12. BMPs are known to signal through the canonical Smad pathway
and the non-canonical mitogen-activated protein kinase (MAPK) pathway. BMP12 triggered robust phosphorylation of
Smad1/5/8 but not Smad2/3 or p38 MAPK in ASCs. The effect was likely conveyed by type I receptors ALK2/3/6, as
phosphorylation of Smad1/5/8 was blocked by the ALK2/3/6 inhibitor LDN-193189 but not by the ALK4/5/7 inhibitor
SB-505124. Moreover, ALK6 was found to be the most abundant type I receptor in ASCs, with mRNA expression 100
to 10,000 times that of any other type I receptor. Collectively, results support the conclusion that BMP12 induces
tenogenic differentiation of ASCs via the Smad1/5/8 pathway.
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Introduction
Tendon injuries are a common cause of pain and disability.
Over 130,000 patients undergo operative tendon repair per
year in the United States [1], resulting in significant health care
costs and social burden. Despite advances in the treatments of
tendon injuries, the clinical outcomes are often poor. Repaired
tendons are materially and functionally inferior to healthy
tendons, even in the long term, and recurrence of injury is
frequent [2,3]. The poor clinical outcomes are largely due to the
inherent limitations of tendon tissues, which are relatively
hypocellular and hypovascular and thus fail to regenerate.
Therefore, cell-based therapies are an attractive future
direction for clinical repair of tendon injuries.
Tendon fibroblasts (TFs) build and maintain the extracellular
matrix of tendons and play an important role in tendon repair.
Although these fully differentiated cells are ideal candidates for
cell-based therapy of tendon injuries, preparation of TFs
requires operative removal of healthy tendon tissue followed by
isolation and expansion of TFs in culture. The surgery may
cause donor site morbidity and expansion of TFs in culture may
take an unacceptably long time due to the low initial yield and
limited expansion potential of primary TFs [2,3]. These
concerns limit the potential of TFs in tendon repair. Bone
marrow-derived mesenchymal stromal cells (BM-MSCs) are
capable of self-renewal and multi-lineage differentiation in
response to specific molecular and physical cues [4,5], and are
therefore promising cell source for tendon repair. Nevertheless,
collecting bone marrow is a painful procedure. Due to the
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limited availability of bone marrow and the low frequency of
MSCs in bone marrow cells, it may take significant time to
expand BM-MSCs in culture to obtain a sufficient number of
cells. Moreover, extensive culture expansion may lead to
genomic alterations that affect cell function [5,6]. Adipose-
derived stromal cells (ASCs) were recently found to contain a
subpopulation of multipotent stem cells [7]. In contrast to bone
marrow, adipose tissue is typically abundant in adults. Surgical
collection of adipose tissue causes little discomfort and donor
site morbidity. Furthermore, ASCs proliferate well in culture and
are minimally immunogenic [8]. Together, these features make
ASCs excellent candidates for cell-based tendon repair.
The molecular cues that induce tenogenic differentiation of
ASCs have yet to be identified. Bone morphogenetic protein
(BMP) 12, 13, and 14, also known as growth differentiation
factor (GDF) 7, 6, and 5 and cartilage-derived morphogenetic
protein (CDMP) 3, 2, and 1, are three closely related members
of the transforming growth factor beta (TGFbeta) superfamily
[9–11]. Unlike other BMPs, they possess low capacity for
inducing chondro-osteogenesis [11–15] and have been
reported to induce ectopic formation of tendon/ligament-like
tissue in vivo [11,16]. These growth factors therefore hold
promise for use as tenogenic cues for ASCs.
To evaluate the tenogenic potential of BMP12, ASCs were
isolated from canine and mouse subcuticular fat tissues. The
dose and time effects of BMP12 on ASC differentiation were
examined using a panel of known tendon markers. Selected
experiments were also performed using BMP14 for comparison
to the literature. Furthermore, the BMP12-induced signaling
pathway was explored in ASCs. Results from this study
advance current understanding of tenogenic signals for ASCs
and provide a basis for future cellular and molecular
approaches for tendon tissue engineering and repair.
Materials and Methods
Animals and reagents
All experimental procedures were conducted in accordance
with the guidelines established by the National Academy of
Sciences and overseen by the Animal Studies Committee at
Washington University in St. Louis. Female adult mongrel
dogs, weighing 20 to 30 kg, were purchased from Covance
(Denver, PA). ScxGFP transgenic tendon reporter mice [17],
kindly provided by Dr. Ronen Schweitzer at Oregon Health &
Science University, were bred in the Washington University
animal facility. Recombinant human BMP12 and BMP2 were
acquired from Pfizer (New York, NY). All other reagents were
purchased from Sigma-Aldrich (St. Louis, MO) unless specified
elsewhere.
Study design
ASCs from a large animal model (canine) were used due to
the translational potential for clinical practice [18–21]. A total of
seven dogs that gave rise to seven ASC isolations were used
in this study. Two ASC isolations were used for the colony
forming unit-fibroblast (CFU-F) assay and for surface marker
determination (n = 2 for each experiment). Two additional
isolations were used to evaluate the differentiation potential of
ASCs (adipogenic, osteogenic, and chondrogenic
differentiation; n = 2 for each). The remaining three ASC
isolations were used in three independent experiments to study
the dose and time effects of BMP12 and BMP14 on ASC
differentiation. ASCs from each isolation were treated in
duplicate. One set of treated cells was used for RNA isolation
followed by quantitative real-time RT-PCR for tendon, cartilage,
and bone marker gene expression (n = 3); the other set of
treated cells was used for protein isolation and the subsequent
Western blot analysis of tendon markers (n = 3). In addition to
ASCs, TFs from the corresponding animals were also isolated
and cultured in parallel as positive controls.
ScxGFP transgenic mice were used to further corroborate
findings from the canine model. In these mice, the expression
of green fluorescent protein (GFP) is driven by the tendon-
specific scleraxis promoter, thus indicating the activation of
tenogenic signaling [17]. ASCs were isolated from nine
ScxGFP mice at the age of 8 weeks. Two of the ASC isolations
were used for the CFU-F assay. Three isolations were treated
with BMP12 and analyzed by immunofluorescent staining for
expression of GFP and tenomodulin and by Western blot for
phosphorylation of Smad proteins and p38 in the presence or
absence of activin-like kinase (ALK) inhibitors (n = 3 for each
analysis). The remaining four ASCs isolations were not treated
and used to determine relative quantities of ALKs and type II
BMP receptor (BMPRII) mRNA in undifferentiated ASCs by
real-time RT-PCR (n = 4). Non-treated TFs were used as
positive control to compare GFP expression in corresponding
ASCs.
Cell isolation and culture
Canine and mouse ASCs were isolated from subcutaneous
fat. The fat tissues (5 g from canine and 1 g from mouse) were
minced into a fine slurry, digested with 0.2% collagenase A
(Roche Diagnostics, GmbH, Mannheim, Germany) in PBS at
37°C for up to 2 h, and then centrifuged at 250 x g for 10 min.
The pellets were re-suspended in minimum essential medium
alpha (alpha-MEM; Meditech Inc, Manassas, VA) and filtered
through a 70 µm nylon mesh to remove undigested tissues.
The filtrates, containing stromal vascular fraction (SVF) cells,
were re-centrifuged as above. The SVF cells were then re-
suspended in alpha culture medium containing 10% FBS, 100
unit/ml penicillin, 100 µg/ml streptomycin, and 2.5 µg/ml
amphotericin B in alpha-MEM and subsequently cultured in
either a T150 (for canine cells) or a T75 (for mouse cells) flask.
Within the next 24 to 48 h, ASCs were selected by removing
unattached cells with two PBS washes. The plastic adherent
ASCs were then maintained in alpha culture medium and
passaged when they were 80-90% confluent at a density of
6000 cells/cm2.
Canine and mouse TFs were prepared from flexor digitorum
profundus and tail tendons, respectively. Canine tendon tissues
were diced into 2-3 mm cubes, while murine tail tendon
fascicles were cut into a few fragments. TFs of either species
were then isolated from respective tissues and cultured as
described for ASCs.
All of the cells were used for experiments at passage 2
unless specified elsewhere.
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CFU-F assay
The CFU-F assay was performed according to the method
described by Schellenberg et al [22]. Briefly, SVF cells isolated
from fat tissue were plated in 96-well plates at densities of
3000, 1000, 300, 100, and 30 cells per well (48 replicas per
density) and cultured in alpha culture medium for 2 weeks. The
cultures were then stained with 0.1% crystal violet solution.
Colony formation was defined by crystal violet staining that
covered at least 50% of surface area of a 96-well. CFU-F
frequency was determined with L-Calc Software (STEMCELL
Technologies) based on Poisson statistics.
Flow cytometry
To quantify surface marker expression on canine ASCs, cells
were dislodged by trypsin-EDTA and stained with FITC-
conjugated anti-CD44 (eBioscience, clone YIX337.8) and APC-
conjugated anti-CD90 (eBioscience, clone YKIX337.2)
antibodies in PBS containing 1% FBS for 30 min at room
temperature. After washes, the stained cells were immediately
examined with FACSCanto II (BD Biosciences) using
FACSDiva software. The cells were gated based on their
forward and side scatter properties to exclude debris and
doublets. Data analysis was performed with FlowJo software
(Tree Star, Inc.) using unstained cells as a negative control to
compare CD44 and CD90 positive populations.
Induction of ASC differentiation
To induce tenogenic differentiation, ASCs were plated in
differentiation medium (alpha-MEM supplemented with 2%
FBS) at a density of 1 × 104 cells/cm2. On the following day, the
cells were treated with the indicated doses of either BMP12 or
BMP14 (R&D Systems, Minneapolis, MN) in the same medium
for up to 14 days with medium change every 2 to 3 days.
Adipogenic differentiation was induced in 100% confluent
ASCs by alternatively growing the cells in adipogenic induction
medium (Lonza, Walkersville, MD) and adipogenic
maintenance medium (Lonza) for two cycles. In each cycle, the
cells were first grown in adipogenic induction medium for 7
days with medium change every 2 to 3 days, followed by 3
days of culture in adipogenic maintenance medium. Afterward,
the cells were washed with PBS, fixed in 10% neutral buffered
formalin, and stained with Oil Red O for lipid droplets.
Chondrogenic differentiation was conducted by growing ASC
pellets (2.5 × 105 cells per pellet) in chondrogenic induction
medium (Lonza) containing 10 ng/ml TGFbeta3 (R&D
Systems) with medium change every 2 to 3 days for up to 28
days. The pellets were then fixed as above, embedded in
paraffin, sectioned to 5 µm thick, and stained with Alcian Blue.
For osteogenic differentiation, ASCs were grown in 6-well
plate pre-coated with collagen I (BD Biosciences, Bedford, MA)
in osteogenic induction medium (alpha-MEM supplemented
with 10% FBS, 50 mg/L ascorbic acid, 10 mM beta-
glycerophosphate, 100 unit/ml penicillin, and 100 µg/ml
streptomycin) at a density of 3 × 103 cells/cm2 for 28 days with
medium change every 2 to 3 days. The culture was then fixed
and stained with 2% Alizarin Red.
RNA isolation and real-time RT-PCR
Cultured ASCs and TFs were directly lysed in culture plates
with Trizol Reagent (Life Technologies, Carlsbad, CA)
according to the manufacturer’s instructions. Chloroform was
then added to the cell lysates (0.2 ml per ml of Trizol). After
vigorous shaking and a brief incubation (2-3 min) on a rotator,
the samples were added to Phase Lock Gel (5 Prime GmbH,
Hamburg, Germany) and centrifuged at 13,000 × g for 6 min at
4 °C. RNA in the resulting upper aqueous phase was purified
with RNeasy Mini Spin Column (Qiagen Sciences, MD, USA)
according to the manufacturer’s instructions. Potential genomic
DNA contamination was eliminated by treating RNA samples
with DNase I (Qiagen) during purification.
Real-time RT-PCR was performed in two steps. In the first
step, total RNA (500 ng) was reversely transcribed into first-
strand cDNA in a 20 µl reaction with random primers using the
SuperScript VILO cDNA Synthesis Kit (Life Technologies)
according to the manufacturer’s instructions. The resulting
cDNA reaction was diluted with 30 µl of nuclease free water. In
the second step, SYBR Green-based real-time PCR was
performed. The PCR, containing 1 µl of the diluted cDNA
reaction from the first step, 1 × QuantiTect Primers (Qiagen) or
1 µM customized forward and reverse primers (Table 1), and 1
× SYBR Green PCR Master Mix (Applied Biosystems,
Warrington, UK) in 20 µl total volume, was carried out in
triplicate with StepOnePlus Real-Time PCR System (Applied
Biosystems). The PCR program was set as the follows: 10 min
at 95 °C for 1 cycle; 15 sec at 95 °C and 40 sec at 60 °C for 40
cycles. A melt curve analysis was performed at the end of each
SYBR Green PCR. The efficiencies of all the primers were over
90%. The relative quantity of target gene expression was
analyzed using the comparative CT (2-∆∆CT) method. GAPDH
was used as endogenous reference gene. The PCR
efficiencies between target genes and GAPDH were
approximately equal. The relative abundance of CD14 and
CD34 mRNAs were expressed as fold change related to mRNA
levels of ASCs at passage 0. In the ASC differentiation study,
the results are shown as fold change related to control ASCs
that received vehicles only. For the expression of ALKs and
BMPRII in non-treated ASCs, the data were compared to a
mouse reference RNA sample purchased from Agilent
Technologies.
Western blot assay
To examine the expression of tenogenic markers, ASCs
were cultured and treated with BMP12 as described above. To
study Smad phosphorylation, ASCs were cultured in 12-well
plates at a density of 1 × 105 cells per well and starved in
differentiation medium overnight. On the following day, the cells
were treated with either BMP12 (1000 ng/ml), BMP2 (200 ng/
ml), or TGFbeta3 (10 ng/ml) for the indicated periods in
duplicates. The dose of BMP12 was chosen based on the
results from this study, which resulted in the strongest
tenogenic effects on ASCs among all the doses examined. The
doses for BMP2 and TGFbeta3 were selected based on those
reported in literatures [23–25]. In cases when the inhibitor
LDN-193189 (Stemgent, San Diego, CA) or SB-505124 was
BMP12 Induces Tenogenic Differentiation of ASCs
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applied, the cells were pretreated with either of the drugs for 15
min prior to the addition of growth factors.
At the end of treatments, the cells were washed twice with
PBS and then lysed in ice-cold RIPA buffer containing 1 mM
DTT and protease inhibitor cocktail (Roche Diagnostics,
Indianapolis, IN). The resulting whole cell lysates were pooled
from the duplicated wells and concentrated with Amicon
Ultra-0.5 Centrifugal 10 K Filter (Millipore Ireland Ltd, Cork,
Ireland). The protein concentrations of these concentrated
samples were determined with a Pierce BCA Protein Assay Kit
(Thermo Scientific, Rockford, IL) according to the
manufacturer’s instructions. 50 µg of each sample were then
separated on 4% to 12% NuPAGE Bis-Tris Mini Gel (Life
technologies) under reducing conditions and subsequently
transferred to nitrocellulose membranes (0.2 µm; Thermo
Scientific). The membranes were blocked with 5% BSA in
TBST buffer containing 10 mM Tris-HCl (pH 8.0), 150 mM
NaCl, and 0.1% Tween 20 and incubated with one of the
following rabbit primary antibodies: phospho-Smad1/5/8 (Cell
Signaling, Danvers, MA), phospho-Smad2 (Cell Signaling),
phosphor-Smad3 (Cell Signaling), SCXA (Abcam, Cambridge,
MA), or Tenomodulin (Santa Cruz Biotechnology) at 4°C
overnight. After three washes with TBST, the membranes were
incubated with Peroxidase-conjugated Anti-Rabbit IgG (H+L)
(Jackson ImmunoResearch, West Grove, PA) for 1 h, and then
washed and detected in Pierce ECL Western Blotting
Substrates (Thermo Scientific). After exposure to X-ray film, the
membranes were stripped, re-blocked, and re-probed with
either of the following rabbit antibodies specific for phospho-
p38 (Cell Signaling), beta-Actin (Abcam), or total Smad1 (Cell
Signaling), as described above. Semi-quantification of band
volume was performed with Quantity One 4.6.5 software (Bio-
Rad) after subtraction of background and normalized by beta-
Actin sample loading control.
Immunofluorescence staining
For tenogenic protein expression, cultured ASCs derived
from ScxGFP tendon reporter mice were fixed with 4%
paraformaldehyde in PBS. After three washes with PBS, the
cells were permeabilized with 0.5% Triton X-100 in PBS,
blocked with 5% normal donkey serum (Jackson
ImmunoResearch) in PBST (PBS containing 0.1% Triton
X-100), and incubated with rabbit anti-Tenomodulin antibodies
(Santa Cruz) at 4°C overnight. After three washes with PBST,
the cells were incubated with Cy3-conjugated Donkey Anti-
Rabbit IgG (H+L) (Jackson ImmunoResearch) for 1 h at room
temperature and then counterstained with bisBenzimide
H33258.
For surface marker expression, canine and mouse ASCs
were fixed as above, blocked with 5% normal donkey serum in
PBS, and then either directly stained with FITC-conjugated rat
anti-CD44 antibodies (eBiosciences, clone IM7), or indirectly
stained with mouse anti-CD29 (BD Biosciences, clone 18/
CD29) or mouse anti-CD90 antibodies (BD Biosciences, clone
5E10) at 4°C overnight followed by incubation with Dylight 488-
conjugated Donkey Anti-Mouse secondary antibodies (Jackson
ImmunoResearch) for 1h at room temperature. After thorough
wash with PBS, the cells were counterstained with
bisBenzimide H33258.
Statistics
Statistical analysis was performed by ANOVA and Fisher’s
PLSD test using StatView 5.0 (SAS Institute Inc.). Statistical
significance was set at P < 0.05. All data are shown as mean ±
standard deviation unless otherwise noted.
Results
Characterization of ASCs
Mesenchymal stromal cell frequencies can be described
using the CFU-F assay [26]. The CFU-F frequency of canine
and mouse SVF cells directly isolated from fat tissues was
determined in 96-well using a limit dilution method [22]. The
assay revealed an average CFU-F frequency of 1 in 90 for
canine cells (Table 2), which was more than three times of that
detected in mouse cells (1 in 339) and at least 100 times of that
previously reported on bone marrow mononuclear cells [27,28].
Table 2. CFU-F frequency of canine and mouse ASCs.
ASC donor Gender Frequency Frequency + 1 S.E. Frequency - 1 S.E.
dog-1 F 1 in 86 1 in 76 1 in 97
dog-2 M 1 in 94 1 in 107 1 in 122
mouse-1 M 1 in 339 1 in 300 1 in 383
mouse-2 M 1 in 338 1 in 296 1 in 387
doi: 10.1371/journal.pone.0077613.t002
Table 1. Customized primers for real-time PCR a.
Canine Forward primer Reverse primer Reference/Accession #
SCX 5'-AAGCTCTCCAAGATCGAGACACTG-3' 5'-AAGAAGGGCCCAGAGTGGCA-3' XM_003431821
Mouse Forward primer Reverse primer  
ALK1 5’-GGCCTTTTGATGCTGTCG-3’ 5'- ATGACCCCTGGCAGAATG-3' Luo et al, 2010
ALK4 5'-CCCCCTTGTTGTCCTCCT-3' 5'-GGCCCCATCTGTCTCACA-3' Luo et al, 2010
ALK5 5'-TGTGCACCATCTTCAAAAACA-3' 5'-ACCAAGGCCAGCTGACTG-3' Luo et al, 2010
ALK7 5'-ATGGCTCCCGAAATGCTTGA-3' 5'-ACAACTCCTCCAACTGAACACC-3' NM_001111030
a Unlisted real-time PCR primers were purchased from Qiagen.
doi: 10.1371/journal.pone.0077613.t001
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The surface marker expression on canine ASCs was
evaluated by immunofluorescent staining. Consistent with
previous reports [29–31], mesenchymal stromal cell markers
CD29, CD44, and CD90 [32] were detected on nearly all
canine (Figure 1A) and mouse (data not shown) ASCs at
passage 2, with distinct expression patterns. Prevalent
expression of CD44 (87.0% ± 0.28%) and CD90 (88.1% ±
7.35%) were also detected on passage 6 canine ASCs by flow
cytometry analysis (Figure 1B).
Low levels of hematopoietic markers such as CD34 have
been reported in human ASCs [30]. To overcome the limitation
of rare-event analysis by flow cytometry, we used the more
sensitive quantitative real-time PCR [33] to evaluate the
expression of CD14 and CD34 in canine ASCs from passage 0
(after initial plating) to passage 5. Although both mRNAs were
detected by real-time RT-PCR in passage 0 ASCs, their
expression levels were substantially decreased in ASCs with
successive passages and became barely detectable after
passage 2 (Figure 1C). This temporal change is in consistent
with that reported in the literature [30].
The differentiation potential of canine ASCs was further
assessed using standard differentiation culture conditions.
Results confirmed that these cells were able to differentiate into
adipocytes, osteoblasts, and chondrocytes, as demonstrated
by Oil Red O, Alizarin Red, and Alcian Blue staining under the
respective culture conditions (Figure 1).
The proliferation capacity of canine ASCs was also
evaluated from passage 1 to passage 6. The result revealed a
stable population doubling time at an average of 1.5 days at
each passage (Figure 1D).
Taken together, the data demonstrated that canine ASCs
prepared in this study contained colony-forming cells that
expressed mesenchymal stromal cell markers and were able to
differentiate into multiple cell types.
BMP12 and BMP14 induced tenogenic differentiation of
ASCs
The dose and time effects of BMP12 and BMP14 on ASC
differentiation were investigated using quantitative real-time
Figure 1.  Characterization of canine ASCs.  Representative images show positive immunofluorescent staining of stromal
markers CD29, CD44, and CD 90 on almost all passage 2 ASCs (A). Representative histograms from flow cytometry analysis reveal
dominant expression of CD 44 and CD90 on passage 6 ASCs (B). The mRNA expression of hematopoietic markers CD14 and
CD34 in ASCs was dramatically reduced with progressive passages (C). The population doubling time (PDT) of canine ASCs was is
shown through passage 6 (D).
doi: 10.1371/journal.pone.0077613.g001
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RT-PCR targeting the tendon markers scleraxis (SCX) and
tenomodulin (TNMD); the tendon matrix genes collagen, type I,
alpha 1 (COL1A1), collagen, type III, alpha 1 (COL3A1), and
decorin (DCN); the cartilage matrix genes aggrecan (ACAN)
and collagen, type II, alpha 1 (COL2A1); and the bone markers
osteocalcin (BGLAP, bone gamma-carboxyglutamic acid-
containing protein) and runt-related transcription factor 2
(RUNX2). In addition to ASCs, gene expression levels in the
corresponding non-treated TFs were assessed in parallel as a
reference for TF phenotype.
SCX is a tendon/ligament-specific transcription factor [34]
that positively regulates TNMD expression [35], and TNMD is
required for TF proliferation and tendon maturation [36]. Our
results revealed that BMP12 dramatically increased SCX
expression in ASCs by up to 9-fold in a dose- and time-
dependent manner (Figure 2A; P < 0.0001 for dose, P = 0.0018
for time). As a result, the SCX levels in the BMP12-treated
ASCs (100 ng/ml and 1000 ng/ml) were similar to those in TFs.
BMP14 also caused a substantial increase in SCX expression
(Figure 2A). The effect was dose- (P < 0.0001) but not time-
dependent (P = 0.18). BMP12 also dose-dependently
increased TNMD expression in ASCs by up to 3-fold (Figure
2B; P = 0.04). No significant change in TNMD was detected in
BMP14-treated ASCs (Figure 2B; P = 0.22). Although neither
BMP12 nor BMP14 increased COL1A1 expression in ASCs,
the resulting COL1A1 levels were comparable to those in TFs
(Figure 2C). Similarly, BMP12 and BMP14 did not alter
COL3A1 expression in ASCs (Figure 2D). Compared to TFs,
COL3A1 levels in BMP12-treated ASCs were significantly
higher at 3 days at 10 and 100 ng/ml doses (P < 0.05) but not
at any other time points. For the BMP14-treated ASCs, in
addition to 3 days (Figures 2D; 10 and 100 ng/ml; P < 0.05 vs.
TFs), higher COL3A1 levels were also detected at 7 days
(Figures 2D; 100 and 1000 ng/ml, P < 0.05 vs. TFs). No
changes were found in DCN expression after either BMP12 or
BMP14 treatment, and the DCN levels in the BMP-treated
ASCs were similar to those in TFs (Figure 2).
When examining the expression of cartilage matrix genes,
both BMP12 and BMP14 dose-dependently augmented ACAN
expression (Figure 2E; P < 0.01 for both BMPs). However, the
effect was not time-dependent, and the resulting ACAN levels
in ASCs remained substantially lower than those detected in
TFs (P <0.0001 for both BMP12 and BMP14). Neither BMP12
nor BMP14 affected COL2A1 expression in ASCs (Figure 2F).
Similar to ACAN, considerably higher levels of COL2A1 were
found in TFs compared to either BMP12- or BMP14-treated
ASCs (P < 0.0001).
With regard to osteogenic gene expression, BMP12 but not
BMP14 dose- and time-dependently suppressed the
osteoblastic BGLAP expression in ASCs by up to 50% (Figure
2G; P = 0.01 for dose, P = 0.02 for time). BMP12 and BMP14
did not affect RUNX2 expression in ASCs, and no significant
difference in RUNX2 expression between BMP-treated ASCs
and TFs were detected (Figure 2H).
Collectively, the results indicated that both BMP12 and
BMP14 were capable of inducing tendon marker gene
expression in ASCs. The most effective dose and treatment
time for both BMPs were 1000 ng/ml for 14 days, respectively.
BMP12 was marginally more potent (based on significant
increase in SCX and TNMD) and selective (based on
downregulation of BGLAP) than BMP14. Therefore, we
focused on BMP12 in the subsequent studies.
Results at the protein level were consistent with the gene
expression results. Western blot analysis demonstrated
increased SCX expression in BMP12-treated ASCs at all three
time points studied, with the highest increase at 14 days
(Figures 3A and 3B). Similarly, TNMD expression was
increased in ASCs with BMP12 treatment, especially at 3 day
and 14 days (Figures 3C and 3D).
To further validate the findings, the ScxGFP transgenic mice,
specifically expressing GFP in tendon tissues under the control
of scleraxis promoter [17], were employed in this study. The
expression of the ScxGFP tendon reporter in ASCs from these
mice was evaluated after BMP12 treatments. As expected,
strong GFP expression was present in the cell nuclei of all TFs
(Figure 4A), but absent in non-treated undifferentiated ASCs
(Figures 4B and 4C, 0 ng/ml). Application of BMP12 induced
dose- (Figure 4B) and time-dependent (Figure 4C) increases in
GFP-positive cells in ASC culture. The resulting GFP-positive
ASCs exhibited spindle-shaped morphology and alignment,
forming TF-like cultures by 14 days (Figure 4B). Moreover,
immunostaining with TNMD antibodies detected dose-
dependent, robust increases in TNMD-immunoreactivity at
perinuclear and cytoplasm regions of these BMP12-treated
cells (Figure 5). Taken together, our data supported that
BMP12 is capable of inducing tenogenic differentiation of
ASCs.
BMP12 induced tenogenic signaling in ASCs via the
Smad1/5/8 pathway
Like other ligands in the TGFbeta superfamily, BMPs bind to
type I and type II receptors (Figure 6A) [37]. Both types of
receptors are transmembrane serine-threonine kinases. Type II
receptors are constitutively active, while type I receptors are
transphosphorylated and therefore activated by type II receptor
upon ligand binding and type I and type II receptor
oligomerization. The activated type I receptors subsequently
activate the canonical Smad pathways and phosphorylate
either Smad1/5/8 or Smad2/3 proteins. The phosphorylated
Smad1/5/8 (p-Smad1/5/8) or Smad2/3 (p-Smad2/3) in turn
form a heteromeric complex with Smad4 and translocate into
nucleus, thus interacting with other transcription factors and
regulating target gene expression.
Although most BMPs activate Smad1/5/8, there are some
exceptions, e.g., BMP3 and BMP11 [38]. Furthermore, there is
promiscuity of BMPs/TGFbetas with regard to their ligand-
receptor relationship [38]. These prior results motivated the
question of whether the Smad1/5/8 or the Smad2/3 pathways
were activated in ASCs after BMP12 treatment. As shown in
Figure 6B, without altering the expression of total Smad1,
BMP12 induced robust phosphorylation of Smad1/5/8 within 15
min, and the strong p-Smad1/5/8 signal persisted even after 60
min of treatment. In contrast, BMP12 resulted in little
phosphorylation of Smad2 (Figure 6C) and Smad3 (Figure 3),
while p-Smad2 and p-Smad3 signals were detected in ASCs
treated with TGFbeta3 for 30 min.
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Figure 2.  BMP12 and BMP14 induce tenogenic gene expression in canine ASCs.  The mRNA expression of the tendon
markers SCX and TNMD was significantly increased in canine ASCs treated with BMP12. In contrast, the expression of the bone
marker BGLAP was dose- and time-dependently reduced by BMP12. Similar changes in gene expression were detected in BMP14-
treated ASCs. The results were determined by quantitative real-time RT-PCR and are shown as fold change related to the
expression level of control ASCs (dashed lines). Log scales are used in (E) and (F). The legend in (A) applies to all of the panels.
doi: 10.1371/journal.pone.0077613.g002
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In addition to the canonical Smad pathway, BMPs are known
to activate non-Smad pathways such as mitogen-activated
protein kinase (MAPK) [39]. Furthermore, the p38 MAPK has
been implicated in tenogenesis [40]. To test if p38 was also
involved in the BMP12-induced tenogenic differentiation of
ASCs, Western blots were performed. There were no
detectable increases in phosphorylated p38 (p-p38) in ASCs
after BMP12 treatment (Figure 6D). Thus, the Smad1/5/8, but
not the Smad2/3 or p38, pathway was activated in ASCs upon
BMP12 treatment.
We next asked which type I receptors activate Smad1/5/8 in
ASCs. To answer this question, the gene expression profile of
all seven type I receptors, namely ALK1 through ALK7, were
surveyed together with the type II receptor BMPRII in ASCs by
quantitative real-time RT-PCR. Interestingly, although all of
these receptors were detectable in non-treated ASCs, the
expression level of ALK6 (also known as BMPR1B), was 100-
to 10,000-fold higher than that of any other receptor evaluated
(P < 0.05; Figure 4), and therefore was more likely to interact
with BMP12.
The selective ALK2, 3, and 6 inhibitor LDN-193189 [41,42] or
ALK4, 5, and 7 inhibitor SB-505124 [43] was then applied to
ASCs to investigate their effects on BMP12-induced Smad1/5/8
phosphorylation. Western blots revealed that LDN-193189
dose-dependently inhibited both BMP12-induced as well as
endogenous Smad1/5/8 phosphorylation (Figure 7A).
SB-505124 blocked TGFbeta3-induced phosphorylation of
Smad2 as well as phosphorylation of Smad1/5/8 in a dose-
dependent manner; nevertheless, the drug did not affect
BMP12-induced Smad1/5/8 phosphorylation (Figure 7B). Thus,
ALK2, 3, and 6 rather than ALK4, 5, and 7 are likely to transmit
BMP12 stimuli to the Smad1/5/8 signaling pathway.
Discussion
To the best of our knowledge, this is the first in-depth study
on the effect of BMP12 on ASC differentiation. Using
tenomodulin, scleraxis, and the ScxGFP tendon reporter as
tenogenic markers, we demonstrated that BMP12 is capable of
dose- and time-dependently inducing tenogenic differentiation
of ASCs. Results further revealed that BMP12 is likely to exert
its effect via the ALK2, 3, and 6 type I receptors, and the latter
in turn activate the Smad1/5/8 signaling pathway. In addition, a
side-by-side comparison between BMP12 and BMP14 revealed
that BMP12 was marginally better as a tenogenic factor.
Together, our findings provide new insights into the cellular and
molecular mechanisms of tenogenic differentiation as well as
new basis for cell-based tendon repair.
Figure 3.  BMP12 increases SCX and TNMD protein expression in ASCs.  Representative Western blots (A and C) and semi-
quantifications (B and D) of band volumes of the corresponding bands are shown.
doi: 10.1371/journal.pone.0077613.g003
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The current study investigated the effects of BMP12 on ASC
differentiation in comparison to BMP14. Our findings are largely
in agreement with previous studies [44,45], reporting increased
expression of scleraxis and tenomodulin at both protein and
mRNA levels in BMP12-treated BM-MSCs [44] as well as
BMP14-treated ASCs [45]. In the current study, BMP12 also
induced the expression of scleraxis promoter-driven GFP in
ASCs in a dose- and time-dependent manner, thus further
demonstrating its role as a tenogenic cue.
In addition to the tenogenic genes, we found that both
BMP12 and BMP14 significantly augmented ACAN expression
in ASCs, similar to observations reported by Park et al [45].
Nevertheless, the effect may not result in cartilage formation,
as proteoglycans are also essential components of tendon [46],
and indeed the resulting expression levels of ACAN in ASCs
remained at least 10-fold lower than those detected in TFs.
Furthermore, no increases in COL2A1 were detected after
either BMP12 or BMP14 treatment. In line with this, it has been
Figure 4.  BMP12 induces scleraxis promoter-driven GFP expression in mouse ASCs.  GFP was expressed by all the TFs
from the ScxGFP transgenic mice in the cell nuclei (A). The number of GFP-positive cells was increased in BMP12-treated ASCs in
a dose- (B) and time- (C) dependent manner. Representative fluorescent and phase contrast images are shown. ASCs in (B) and
(C) were treated with BMP12 for 14 days and at a concentration of 1000 ng/ml, respectively. The scale bar = 50 µm and applies to
all of the panels.
doi: 10.1371/journal.pone.0077613.g004
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shown that BMP14 is insufficient to directly induce
chondrogenic differentiation and chondrocyte maturation in a
micromass culture of limb bud mesenchyme cells [15], and
BMP12 and BMP13 have been reported to have little impact on
COL2A1 expression in MC615 chondrocytes as well [13].
Future chondrogenic assays after longer term BMP12
treatment (e.g., 21 or 28 days) may be helpful to clarify the
effect on BMP12 in chondrogenic differentiation of ASCs.
In contrast to their effects on teno-chondrogenic marker gene
expression, neither BMP12 nor BMP14 increased the
osteogenic marker OCN and RUNX-2 expression in ASCs. As
a matter of fact, a dose- and time-dependant decrease in OCN
expression was detected in the BMP12-treated ASCs. These
findings further support the notion that both BMPs promote
tenogenic rather than osteogenic differentiation of ASCs.
Nevertheless, because osteogenesis was not the focus of this
study, our analysis in this aspect is not definitive. Future
evaluations are necessary to fully reveal the impact of BMP12
on osteogenic differentiation of ASCs. These studies may
include examination of additional osteogenic marker such as
osterix and alkaline phosphatase and mineralization assays.
Our results demonstrated that BMP12 preferentially activates
Smad1/5/8, but not Smad2/3 and p38 signaling. Interestingly,
besides BMP12, the osteogenic factor BMP2 also activates
Smad1/5/8. As discussed above, because our evaluation on
osteogenesis in BMP12-treated ASCs is not definitive, we
cannot completely rule out the involvement of BMP12 in
osteogenic differentiation. However, our observation of a dose-
dependent decrease of OCN in BMP12-treated ASCs is in
sharp contrast to the substantial increase of OCN in stem cells
exposed to BMP2 [13,14,47]. It is unclear why activation of the
same pathway leads to the different cellular responses. One
possible explanation is that BMP12 and BMP2 differentially
activate individual Smad proteins within the Smad1/5/8 group
and therefore result in different transcriptional responses.
Smad1 [48,49] and Smad5 [49] signaling pathways have been
associated with osteogenesis, whereas activated Smad8 was
reported to directly induce tenogenic differentiation of MSCs in
vitro and in vivo [50,51]. Thus, BMP12 may result in primarily
Smad8 phosphorylation, while BMP2 may result in primarily
Smad1 and Smad5 phosphorylation. Alternatively, the kinetics
of Smad phosphorylation as well as the activities, stabilities,
and localizations of phosphorylated Smads may be modified
via activation of ligand-specific co-receptors or other non-
canonical pathways [52,53], thus specifying the downstream
transcriptional events. Additional studies are necessary to
clarify the details of the signaling.
This study further revealed that the BMP12-triggered
phosphorylation of Smad1/5/8 was fully abolished by the ALK2,
3, and 6 blocker LDN-193189 but not by the ALK4, 5, and 7
inhibitor SB-505124. These findings, together with the
overwhelming expression pattern of ALK6 mRNA in ASCs, lead
to our hypothesis that BMP12 might preferentially signal
through ALK6 to activate Smad1/5/8 pathway and therefore
induce tenogenic differentiation of ASCs. In line with this
hypothesis, it has been reported that BMP14 almost exclusively
binds to the ALK6 type I receptor with high specificity both in
vivo [54] and in vitro [55]. Comparing the sequences of human
Figure 5.  BMP12 increases TNMD protein expression in mouse ASCs.  The expression of TNMD protein (in red) in ASCs from
ScxGFP transgenic mice was dose-dependently increased after a 14-day treatment with BMP12. Representative fluorescent images
are shown. Cell nuclei were counterstained with H33258 (in blue). The scale bar = 50 µm and applies to all panels.
doi: 10.1371/journal.pone.0077613.g005
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BMP14 (P43026) and BMP12 (NP_878248.2) revealed that the
single Arg438 residue responsible for ALK6 binding specificity
[55] is conserved between the two molecules. Moreover,
overexpression of all seven ALK receptors demonstrated that
ALK3 and ALK6 but not ALK1, 2, 4, 5, and 7 are capable of
conveying BMP12 signaling [56]. Because LDN193189 at
effective dosages is toxic to the cells in extended culture, we
were unable to directly test its effect on BMP12-induced
tenogenic differentiation of ASCs. Future studies using gene
deletion or silencing will help to verify our signaling hypothesis
and advance our understanding of the BMP12-induced
tenogenic signaling pathway in ASCs.
Our results demonstrate that ASCs have the capacity to
differentiate into TF-like cells after BMP12 treatment; however,
a concern remains that BMP12 may induce bone formation by
ASCs in vivo. Although evidence provided from this study and
from the literature [11–15] suggests that the risk for this is low,
current data cannot exclude the possibility of osteogenesis.
Zuk et al. [47] recently reported that ASCs may not respond to
the osteogenic induction provided by BMP2, and speculated
that this result was due to the lack of expression of the
osteogenic response genes necessary for the BMP effect. In
contrast, others groups have claimed that ASCs do indeed
respond to BMP2 with osteogenic differentiation [57]. The
disparate results may be due to the heterogeneous nature of
ASCs or due to variations in cell culture conditions.
Taken together, this study demonstrated BMP12 as a potent
tenogenic growth factor, inducing ASCs to form TF-like cells.
Results further elucidated the signaling pathway leading to
tenogenesis of ASCs. These findings provide a cellular and
molecular basis for developing novel therapeutic strategies. For
example, ASCs along with BMP12 can be delivered to the site
of tendon injury during operative tendon repair to improve
tendon healing or prevent tendon degeneration.
Figure 6.  BMP12 activates Smad1/5/8 signaling pathway in ASCs.  The interaction of BMPs with type I and type II receptors
leads to the transphosphorylation of type I receptors by type II receptors (A). The type I receptors are the signaling receptors that
activate Smad signaling pathways. There are seven known type I receptors, namely ALK1 through ALK7. They are typically
separated into two groups: ALK1, 2, 3, and 6 phosphorylate Smad1/5/8; ALK4, 5, and 7 phosphorylate Smad2/3. LDN-193189 and
SD-505124 are selective inhibitors for ALK2, 3, 6 and ALK4, 5, 7, respectively (A). For simplicity, ALK1 is not shown in the figure.
Smad1/5/8 (B) but not Smad2 (C) and p38 (D) in ASCs was phosphorylated by BMP12 (1000 ng/ml) as detected by Western blot.
BMP2 (200 ng/ml) and TGFbeta3 (10 ng/ml) were used as positive controls for the induction of phosphorylation of Smad1/5/8 and
Smad2, respectively.
doi: 10.1371/journal.pone.0077613.g006
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Supporting Information
Figure S1.  Canine ASCs (A) were induced to differentiate
toward adipocytes (B), osteoblasts (C), and chondrocytes
(D), showing positive staining for Oil Red O (B), Alizarin
Figure 7.  ALK2, 3, and 6 receptors are involved in BMP12
signaling.  The BMP12-induced phosphorylation of Smad1/5/8
was dose-dependently blocked by the selective ALK2, 3, and 6
inhibitor LDN-193189 (A) but not by the ALK4, 5, and 7 inhibitor
SB-505124 (B). The latter blocked the phosphorylation of
Smad2 induced by TGFbeta3. Representative Western blots
are shown. The Smad1 blots were used as sample loading
controls.
doi: 10.1371/journal.pone.0077613.g007
Red (C), and Alcian Blue (D), respectively. Scale bar = 50
µm in A, B, D and 500 µm in C.
(TIF)
Figure S2.  The mRNA expression of DCN in ASCs was not
affected by either BMP12 or BMP14 treatment. The results
were determined by quantitative real-time RT-PCR and are
shown as fold change related to the expression level of control
ASCs (dashed line).
(TIF)
Figure S3.  BMP12 had little effect on induction of Smad3
phosphorylation, while phosphorylated Smad3 (p-Smad3)
was detected in TGFbeta3-treated ASCs.
(TIF)
Figure S4.  All seven type I ALK receptors as well as the
type II BMPRII genes were expressed in ASCs. The results
were detected by quantitative real-time RT-PCR and are shown
as fold change related to the gene expression level in a
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